You are here:Home-Research Areas-Other Indications-Fibrosis

Request The Product List ofFibrosis Fibrosis

Cat. No. Product Name CAS No. Information
PC-61128

PAT-1251

2007885-39-2

PAT-1251 (PAT 1251, PAT1251) is a potent, selective and orally bioavailable lysyl oxidase-like 2 (LOXL2) inhibitor with IC50 of 0.71 uM in human whole blood assays, with high selectivity over LOX (400-fold) and other amine oxidases; exhibits efficacy in mouse bleomycin lung fibrosis model.

Fibrosis

Phase 1 Clinical

PC-60402

GLPG-1690

1628260-79-6

GLPG-1690 is a first-in-class, potent, competitive autotaxin inhibitor with Ki/IC50 of 15 nM/131 nM; inhibits ATX-induced LPA 18:2 production in mouse, rat, and healthy donor plasma with IC50 of 418 nM, 542 nM, and 242 nM, respectively; shows no CYP3A4 TDI and decreased hERG inhibitory activity (IC50=15 uM), and good pharmacokinetic profile for treatment idiopathic pulmonary fibrosis.

Fibrosis

Phase 2 Clinical

PC-60232

GLPG-1837

1654725-02-6

GLPG-1837 (ABBV-974) is a potent, orally available CFTR potentiator with EC50 of 3 nM and 339 nM on F508del and G551D CFTR, respectively; shows enhanced efficacy on CFTR mutants harboring Class III mutations compared to Ivacaftor.

Cystic Fibrosis

Phase 2 Clinical

PC-60231

GLPG-2222

1918143-53-9

GLPG-2222 (ABBV-2222, Galicaftor) is a novel potent and efficacious CFTR corrector with EC50 of 5 nM; is highly potent (5 nM) and efficacious in cells from multiple CF patient donors that have F508del homozygous mutation; shows potential in clinical trials in patients harboring the F508del CFTR mutation on at least one allele.

Cystic Fibrosis

Phase 2 Clinical

PC-60070

GSK-3008348 hydrochloride

1629249-40-6

GSK-3008348 hydrochloride is a novel potent, selective integrin αvβ6 antagonist for the treatment of idiopathic pulmonary fibrosis (IPF).

Cystic Fibrosis

Phase 1 Clinical

PC-60069

GSK-3008348

1629249-33-7

GSK-3008348 is a novel potent, selective integrin αvβ6 antagonist for the treatment of idiopathic pulmonary fibrosis (IPF).

Cystic Fibrosis

Phase 1 Clinical

PC-42213

BMS-986020

1257213-50-5

BMS-986020 (BMS986020, AM-152) is a potent, selective, orally available LPA1 receptor antagonist for treating idiopathic pulmonary fibrosis.

Cystic Fibrosis

Phase 2 Clinical

Request The Product List

* Indicates a Required FieldYour information is safe with us.

  • *Product List:
  • *Applicant name:
  • *Email address:
  • *Organization name:
  • *Country:
  • Additional Information:
Contact Us sales@probechem.com